Search 

ImmunoBiochem is an immuno-oncology biopharmaceutical company that has developed a disruptive approach to targeting unique proteins amplified in cancer secretomes. These targets are secreted from cancer cells and accumulate in tumors, but not in normal tissues, and are constantly recycled in the tumor microenvironment. This novel approach enables the selective and efficacious delivery of immunomodulatory and chemotherapeutic payloads into relevant subsets of cells within the tumor microenvironment, including tumor cells, immune cells and tumor-supporting stroma.
ImmunoBiochem’s IMB-213I candidate delivers a potent innate immune system agonist for the treatment of highly heterogeneous solid tumors, such as TNBC, pancreatic and ovarian cancers.
ImmunoBiochem's IMB-212 candidate delivers a potent cytotoxic payload into difficult-to-treat solid tumors, particularly where no suitable surface targets and no biologics are available.

University of Calgary based accelerator

Partnership between Ministry of Foreign Affair and Ministry of Higher Education and Science of Denmark. Help danish high-tech companies and research instututes to enter Chinese market and find Chinese collaborators

The Innovation Forum is an accelerator for healthcare ventures. It is supported by a global grassroots network of over 10,000 innovators who seek to improve human health and wellbeing by translating cutting-edge science into innovative products and services. We focus on the future and the evolution of today’s technologies, which range from the nascent stage to the cusp of commercial application.

Company Description

CRO Preclinical
In vivo efficacy evaluation in oncology

Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trial outcomes.

Venn Biosciences innovates cancer diagnostics using Artificial Intelligence (AI) and next-gen mass spectrometry, unlocking glycoproteomics for Biomarker and Target Discovery.

InvivoSciences, Inc. (IVS) is a preclinical stage biotech company with a team of drug development experts, including Dr. Joseph Schlessinger, who developed various therapies including, a blockbuster drug - Sutent.
With an increasingly aging population with chronic diseases such as diabetes, heart failure is an urgent and critical challenge without an effective solution. There have been no successful phase III trials in worsening chronic heart failure or heart failure with preserved ejection fraction (HFpEF). Large clinical trials required for the heart failure trials have been the bottleneck. There is clear evidence showing that genetic factors drive heart failure development. Our mission is to cure heart failure one gene at a time.
We have leveraged our advanced artificial intelligence integrated breakthrough in precision medicine discovery platform using patient-derived human micro heart on a chip, NuHeart™, to identify and validate multiple drug pipelines rapidly as well as help us to determine biomarkers and stratify the patients for a clinical trial recruitments. Our precision heart failure pipelines are at least ten times more cost-effective to develop, especially during their clinical stages. Using our platform, we have developed two pipelines of small-molecule candidates for difficult to treat, genetically defined heart failure conditions. Our Pipelines of precision medicines have the potential to deliver better outcomes for patients fighting hard to treat heritable heart disease.
Collaborative patient-driven precision medicine-based drug development empowered with our novel platform will lead to meaningfully better outcomes for heart failure patients, which we refer to as InvivoSciences’ discovery engine to develop target therapies. Our lead program includes candidates in preclinical development for monogenetic heart failures. To date, IVS raised $8.5 Million non-dilutive funding from founders, board, commercial contracts, and grants. The funds have been used to create a portfolio of assets (breakthrough discovery platform, NuHeart™, three genetically defined disease models, current discovery programs, and a strong portfolio of patents including both US and international.
To join and support our drug discovery programs forward, InvivoSciences is seeking world-class life science investors and strategic partners for our Series A round for growth capital for $10 M in two trunches for commercial growth and accelerating our drug program.